Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

33.60USD
7:25pm BST
Change (% chg)

$0.37 (+1.11%)
Prev Close
$33.23
Open
$33.13
Day's High
$34.05
Day's Low
$32.81
Volume
38,137
Avg. Vol
164,606
52-wk High
$54.45
52-wk Low
$27.85

Seidenberg, Beth 

Dr. Beth C. Seidenberg, M.D. is an Independent Director of the Company. Dr. Seidenberg is a General Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. Dr. Seidenberg was previously the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc., a biotechnology company. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, and Merck. Dr. Seidenberg received a B.S. from Barnard College and an M.D. from the University of Miami School of Medicine and completed her post-graduate training at The Johns Hopkins University, George Washington University and the National Institutes of Health. Dr. Seidenberg serves on the board of directors of TESARO and Epizyme, Inc.

Basic Compensation

Total Annual Compensation, USD 50,000
Restricted Stock Award, USD 96,150
Long-Term Incentive Plans, USD --
All Other, USD 176,789
Fiscal Year Total, USD 322,939

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Isaac Ciechanover

3,366,820

Utpal Koppikar

--

Joseph Newell

1,641,820

Christopher Haqq

3,298,020

Mitchall Clark

1,402,910

Gad Soffer

3,098,040
As Of  31 Dec 2017